STM BIOSOLUTIONS

Bringing Quality to Healthcare.



Covid-19 Treatments

Remdesivir

Molnupiravir

Paxlovid

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

About Us

STM BioSolutions is an emerging leader in the distribution of various innovative medical devices, pharmaceuticals, and biopharmaceuticals around the world. We seek to deliver protections against public health threats through a pipeline comprising of innovative products and therapeutics. We do what we do because we see the opportunity to create a better, more secure world. A world where preparedness empowers protection from the variety of threats we face, where peace of mind prevails.

As a response to the Covid-19, we have formed strategic alliances with several key Pharmaceutical, and Personal Protective Equipment Manufacturers globally. Bangladesh has been setting the bar high for generic medicine for the past 80 years and we are proud to be able to inform you that our Bangladeshi Pharmaceutical Manufacturing Partners have been the first in the world to bring the generic versions of Molnupiravir and Paxlovid along with many other generic drugs to market. The plants used in manufacturing these possess approvals from regulatory bodies such as UKMHRA, TGA, EUGMP, WHO GMP and have been a symbol of where quality meets .

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

FAQ

1. Regulatory body approvals for the facilities that are manufacturing the above drugs:

UKMHRA, TGA, EUGMP, WHO GMP

2. A Standard Operating Procedure:

- Non-Disclosure Agreement
- Letter of Intent From Buyer
- Soft Corporate Offering
- Buyer will share PO & Customer Profile form filled out.
- Proof of Funds is Required if buyers' ability to Purchase cannot readily be determined.
- Pro-Forma Invoice
- Full payment via TT or Full transactional amount loaded into US based third-party escrow to be released on shipping documents for an additional charge.

3. The following information for each of the products:

i) Pricing

Please contact sales team for quote.

ii) Minimum Order Quantity (MOQ) as well as maximum capacity per month

Remdesivir: MOQ 10,000 vials

Molnupiravir: MOQ 10,000 packs (10 / pack)

Paxlovid: MOQ 2,000 packs (6 / pack)

Maximum Capacity: STM has a huge capacity in terms of access to production allocation through various manufacturing partners, kindly let us know the requirement. We will accommodate accordingly.

iii) Lead time following order placement at MOQ:

1 month to handover the goods to the selected freight forwarder.

iv) Shipping Terms:

FOB, CIF Available for select countries for excess charge.

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Contact Us

STM BioSolutions L.L.C.

Website:

www.stmbiosolutions.com

Email:

info@stmbiosolutions.com

Phone:

US: +1 (682) 554-0824 | +1 (469) 922-9045
Canada: +1 (647) 225-3525

Locations:

US Office

Wyoming
300 N Gould St STE R,
Sheridan, WY 82801

Texas
5511 Parkcrest Dr STE 207,
Austin, TX 78731

Canada Office

Ontario
706- 1 Concorde Gate,
North York, ON M3C 3N6

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

SARS-CoV-2 Viral Infection & Progression



STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Current Approved Treatment for COVID-19

Medicine	Dosage & Administration	Requirement	Indication
Remdesivir	Injectable & IV infusion	Hospital Setting	Moderate to Severe Illness
Tocilizumab	Injectable & IV infusion	Hospital Setting	Moderate to Severe Illness
Casirivimab & Imdevimab	Injectable & IV infusion	Hospital Setting	Mild to Moderate Illness

and recently.....

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

For **Mild to Moderate** Illness

2 Oral Anti-COVID medicines has been authorized by **US FDA**

- MOLNUPIRAVIR
- NIRMATRELVIR Co-packaged with RITONAVIR

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Generic Paxlovid

Nirmatrelvir INN 150 mg Tablets and Ritonavir USP 100 mg Tablets

World's 1st US FDA Authorized

ORAL ANTI-COVID MEDICINE

for the people of Bangladesh

STM BIOSOLUTIONS

Bringing Quality to Healthcare.



STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Mechanism of Action



SARS-CoV-2 RNA is translated into a Polyprotein chains which are needed for viral replication.

Proteases enzymes act like scissors and cut polyprotein chains into separate proteins.

Nirmatrelvir is a main protease inhibitor that prevents this cutting process and stops virus to make more copies.

Ritonavir inhibits the metabolism of Nirmatrelvir and increases its plasma concentration.

Stops the formation of viral protein and infection cascade

Mechanism of Action

- **Nirmatrelvir** is a novel oral antiviral which inhibits main protease enzyme of SARS-CoV-2. This enzyme is an essential enzyme for formation and replication of all variants of Coronavirus and is less affected by mutation.

- **Ritonavir** is co-administered with Nirmatrelvir as a pharmacokinetic enhancer resulting in higher systemic concentrations and longer half-life of Nirmatrelvir

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Generic Paxlovid

Nirmatrelvir INN 150 mg Tablets and Ritonavir USP 100 mg Tablets

1st US FDA Authorized Oral Anti-COVID Medicine

FDA

US FDA has issued an Emergency Use Authorization of its first oral anti-COVID medicine, the combination of Nirmatrelvir and Ritonavir, to treat mild to moderate COVID-19 in adults and paediatric patients 12 years of age and older weighing at least 40kg.

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Proven Clinical Efficacy

Clinical study on 2246 patients with COVID-19 have shown 10-fold decrease in viral load among patients taking Generic Paxlovid compared to placebo:



Effective and Safe against all COVID-19 Variants

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Generic Paxlovid

Nirmatrelvir INN 150 mg Tablets and Ritonavir USP 100 mg Tablets

1st US FDA Authorized Oral Anti-COVID Medicine

Dosage And Administration

The recommended dose of Generic Paxlovid is one strip every 12 hours for 5 days.

Tab. Generic Paxlovid 1 strip+0+1 strip, for 5 days

Each strip contains 2 tablets of Nirmatrelvir INN 150 mg and 1 tablet of Ritonavir USP 100 mg.

Can be taken with or without food

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Generic Paxlovid

Nirmatrelvir INN Tablets and Ritonavir USP Tablets

1st US FDA Authorized Oral Anti-COVID Medicine

Dosage And Administration

Dose reduction for **Moderate Renal Impairment**
(eGFR ≥ 30 to < 60 mL/min) is
150mg Nirmatrelvir and 100mg Ritonavir twice daily for 5 days

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Manufactured from World Class Facility

UK MHRA

TGA Australia

Caution

- Not recommended in patients with severe renal impairment (eGFR < 30 mL/min)
- Not recommended in patients with severe hepatic impairment
- Ritonavir can be used in Pregnancy. No available human data on the use of Nirmatrelvir.

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Brand Profile

Brand Name	Generic Paxlovid
Generic Name	Nirmatrelvir INN 150mg Tablets & Ritonavir USP 100mg Tablets
Strength	2 Strips (Combipack) Each strip contains 2 light pink color tablets of 150mg Nirmatrelvir and 1 white color tablet of 100mg Ritonavir
Therapeutic Class	Antiviral
Dosage Form	Tablet
Pack Size	2 Strips (3 Tablets/Strip)
International Brand	PAXLOVID (Pfizer, USA)

Dosage And Administration

The recommended dose of | Generic Paxlovid is one strip every 12 hours for 5 days.

Tab. Generic Paxlovid 1 strip+0+1 strip, for 5 days

STM BIOSOLUTIONS

Bringing Quality to Healthcare.



Generic Molnupiravir

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

U.S. FOOD & DRUG ADMINISTRATION

Home / News & Events / FDA Newsroom / Press Announcements / Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

FDA NEWS RELEASE

Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

For Immediate Release: December 23, 2021

Español

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck's molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Molnupiravir is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth. It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

STM BIOSOLUTIONS

Bringing Quality to Healthcare.



U.S. FOOD & DRUG ADMINISTRATION

Search Menu

Home / News & Events / FDA Newsroom / Press Announcements / Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

FDA NEWS RELEASE

Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults

For Immediate Release: December 23, 2021

Español

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck's molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Molnupiravir is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth. It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Mechanism of Action



- Molnupiravir is a Nucleotide-Analogue of Cytosine and Uracil and causes coding error during viral RNA transcription.
- Molnupiravir inhibits viral propagation through transition mutations into the SARS-CoV-2 genome.

Makes Replication Error & Stops Viral Load

STM BIOSOLUTIONS

Bringing Quality to Healthcare.



STM BIOSOLUTIONS

Bringing Quality to Healthcare.



STM BIOSOLUTIONS

Bringing Quality to Healthcare.



Can be taken with or without food

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Experts' Take on Molnupiravir

- To treat only RT-PCR COVID positive patients
- Must be used fewer than 5 days from the symptoms' onset
- Ideal for elderly patients suffering from mild to moderate COVID symptoms at home
- Cannot be used to treat asymptomatic patients

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Caution

- Molnupiravir is not recommended in pregnancy.
- Not recommended to children and adolescents aged **less than 18 years**.

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Brand Profile

Brand Name	Generic Molnupiravir
Generic	**Molnupiravir**
Strength	**200mg**
Dosage Form	**Capsule**
Therapeutic Class	Antiviral
Pack Size	**10's**
International Brand	Lagevrio MERCK, USA

DOSAGE AND ADMINISTRATION:
The recommended dose of Mo vir is four 200 mg capsules, every 12 hours for 5 days.

Cap. Generic Molnupiravir 200 mg 4+0+4, for 5 days

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

BREAKING NEWS

"A 3-Days Course of REMDESIVIR in Mild-Moderate COVID-19 cases resulted in an 87% lower risk of Hospitalization or Death than Placebo"



STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Generic Remdesivir

US FDA expands its approval of Remdesivir to COVID-positive patients (12 years & above) who are not hospitalized

Recommended Dose for Non-Hospitalized Patients:

3 Days Course with **REMDESIVIR** within **Seven Days** of the start of COVID-symptoms in Mild-Moderate COVID-19 cases was found to Reduce the Risk of Hospitalization and Death by **87%**.

Recommended Dose:

Day 1: 200 mg IV Infusion

Day 2 to Day 3: 100 mg IV Infusion

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Generic Molnupiravir

Recommended Dose for Hospitalized Patients:

5 Days Course with **REMDESIVIR** had **31%** Faster time to recovery from hospitals than those who received Placebo.

Recommended Dose:

Day 1: 200 mg IV Infusion
Day 2 to Day 5: 100 mg IV Infusion

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

ANTIVIRALS

Difference			
Generic	**Molnupiravir**	**Nirmatrelvir co-packaged with Ritonavir**	**Remdesivir**
Indication	Mild-Moderate illness	Mild-Moderate Illness	Moderate-Severe Illness
When to take	Within 5 days of Positive-COVID-19	Within 5 days of Positive-COVID-19	After Hospitalization
Recommended Age	18 years & above	12 years & above	12 years & above
Full Course For Treatment (5 Days)	4 Boxes (40 Capsules)	5 Boxes (30 Tablets)	6 Vials
Mechanism of Action	Nucleoside Analogue	Inhibits Main Protease Enzyme	Inhibits RNA-Dependent RNA Polymerase
Recommended Dose	Cap. 4+0+4, for 5 days	Tab. 1strip(3 tablets)+0+1strip(3 tablets) for 5 days	Day 1- 200mg IV Infusion Day 2- Day 5- 100mg IV Infusion
Pregnancy	Not recommended	May be given	May be given
Kidney Patient	No dose adjustment	50% Dose reduction for eGFR ≥ 30 to < 60 mL/min (moderate case) Not recommended for eGFR < 30 mL/min (severe case)	No dose adjustment
Regulatory Approval	UK MHRA & US FDA Approved	US FDA Approved	US FDA Approved

STM BIOSOLUTIONS

Bringing Quality to Healthcare.

Thank You